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background:  With the increasing use of novel oral anticoagulants (NOAC), patients are often on both NOACs (apixaban, rivaroxaban and 
dabigatran) and antiplatelet therapy (aspirin or clopidogrel). However, it remains unclear how the addition of antiplatelet therapy to NOACs impacts 
stroke prevention and bleeding risk.
methods:  To examine the safety and efficacy of dual therapy (NOAC + antiplatelet) compared with NOAC alone in the prevention of 
thromboembolic events in patients with nonvalvular atrial fibrillation, a meta-analysis was performed. Data was pooled from randomized controlled 
trials (RCTs) that compared NOACs to warfarin in order to compare thromboembolic and bleeding event rates among those on both NOAC and 
antiplatelet therapy to NOAC alone.
results:  Data from four RCTs, with a total of 28,511 patients, were included in the meta-analysis. Patients on both NOAC and antiplatelet agents 
had a composite risk of thromboembolic events that was higher than patients on NOAC alone (RR 1.34; 95% CI 1.17, 1.55) as well as a higher risk 
of bleeding (RR 1.29; 95% CI 1.20, 1.38).
conclusions:  In the data available thus far regarding novel oral anticoagulants apixaban, rivaroxaban and dabigatran, patients on NOACs and 
antiplatelet therapy have higher rates of both thromboembolic events and major bleeding than those on NOACs alone. In this meta-analysis, patients 
were not randomized to antiplatelet therapy use and thus further prospective studies are needed.
 
